Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated -- Ignore unavailable to you. Want to Upgrade?

To: ladyPI who wrote (49616)	1/22/2019 5:02:51 PM
From: JJINV	Read Replies (2) \| Respond to of 63307

EXCELLENT POST. ... wow. So why didn’t the company care enough to provide that information to shareholders and stakeholders ... ??

To: ladyPI who wrote (49616)	1/22/2019 5:40:57 PM
From: recarte	4 Recommendations Recommended By bobbseytwins2001 diaperdaddy erippetoe rodneyh07 Read Replies (1) \| Respond to of 63307

Thank you Lady and Ronin....that along with Idaho's first response are great news. Much better than my mood Thursday night (sorry for the email Lonnie, forgot you were going on vacay). Having the issues kind of already known (and addressable) but thought they could be addressed post approval is still a break down in communication. Hey, we have these 4 things. We assume we can do something about them post thumbs up. It should have been said to the FDA. The FDA should have said yeah or nope. Breakdown somewhere. I'm bummed, but optimistic. We have a great drug that will help women who are desperately ill....get it to them as fast as possible. I choose not to tweet the FDA sec...don't poke the bear.